Patents Represented by Attorney, Agent or Law Firm Wilson Sonsini Goodrich and Rosati
  • Patent number: 8142803
    Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: March 27, 2012
    Assignee: Magceutics, Inc.
    Inventors: Guosong Liu, Fel Mao
  • Patent number: 8145519
    Abstract: The present invention is designed to develop research protocols for clinical trials. The invention also can track and enhance subject compliance with a research protocol. The invention further provides evaluability data related to subject performance in the clinical trial. According to an alternative embodiment of the invention, a portable electronic device is used to query and collect data from the subject.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: March 27, 2012
    Assignee: invivodata®, Inc.
    Inventors: Michael Hufford, David Peterson, Jean Paty, Saul Shiffman
  • Patent number: 8143226
    Abstract: A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydroguaiarectic acid (NDGA) and doxorubicin.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: March 27, 2012
    Assignee: The Regents of the University of California
    Inventors: Ira Goldfine, John Kerner, Betty A. Maddux, Michael Campbell, Jack F. Youngren, Peter Kushner
  • Patent number: 8143001
    Abstract: The invention relates to methods for analysis of nucleic acid methylation status, and fragmentation and/or labeling and/or immobilization of nucleic acids. More particularly, the invention relates to methods for fragmentation and/or labeling and/or immobilization of nucleic acids comprising labeling and/or cleavage and/or immobilization at abasic sites.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: March 27, 2012
    Assignee: NuGEN Technologies, Inc.
    Inventors: Nurith Kurn, Geoffrey A. Dafforn
  • Patent number: 8142928
    Abstract: Systems and methods for configuring tabs on a rechargeable battery may include a current collector comprising one or more collector foil and one or more tabs connected to the collector foil for conveying generated current from the current collector. The tabs may be configured to extract greater capacity from the battery electrodes so that the resulting battery may exhibit higher performance. The tabs may be configured so that the length of the tab is greater than the height of the collector foil so the tab may cover the height of the collector foil and may protrude from the foil.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: March 27, 2012
    Assignee: BASVAH LLC
    Inventors: George E. Blomgren, On Chang, Dania Ghantous, Ou Mao
  • Patent number: 8142775
    Abstract: Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: March 27, 2012
    Assignee: Althea Technologies, Inc.
    Inventors: Bhami C. Shenoy, Teresa G. Cachero, John Shin, Lekai Zhang, Aftab Rashid, Danica Grujic, Reena J. Patel, Margaret Ellen McGrath
  • Patent number: 8143269
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: March 27, 2012
    Assignee: Calcimedica, Inc.
    Inventors: Jeffrey P. Whitten, Yazhong Pei, Kenneth A. Stauderman, Jack Roos
  • Patent number: 8142781
    Abstract: The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: March 27, 2012
    Assignee: ArmaGen Technologies, Inc.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 8137302
    Abstract: The lateral flow between adjacent lung segments is occluded by blocking collateral flow channels with particles. A gas flow is established from one lung segment through the flow channels in an intermediate fibrous septum, and out through the adjacent lung segment. Particles entrained in the gas flow become lodged in the collateral flow channels to eventually block flow.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: March 20, 2012
    Assignee: Pulmonx Corporation
    Inventors: Nikolai Aljuri, Jose G. Venegas, Ajit Nair, Rodney C. Perkins
  • Patent number: 8136526
    Abstract: Lung conditions are treated by implanting a flow restrictor in a passageway upstream from a diseased lung segment. The restrictor will create an orifice at the implantation site which inhibits air exchange with the segment to induce controlled atelectasis and/or hypoxia. Controlled atelectasis can induce collapse of the diseased segment with a reduced risk of pneumothorax. Hypoxia can promote gas exchange with non-isolated, healthy regions of the lung even in the absence of lung collapse.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: March 20, 2012
    Assignee: Pulmonx Corporation
    Inventors: Rodney C. Perkins, Nikolai Aljuri, Ajit Nair
  • Patent number: 8136520
    Abstract: An obturator for a bronchial tube or tubule of a human or animal lung includes a blocking element (92) and a securing element (90). The blocking element serves to seal the tube or tubule against the passage of fluid past the obturator when the obturator is disposed in a bronchial tube or tubule. The securing element serves to retain the blocking element in position. The blocking element comprises a substantially cylindrical plug of biocompatible, resiliently deformable closed-cell foamed plastics material, such as PVC. The securing element includes a stent having barbs (98) to engage and retain the blocking element. The stent also has anchors (100) to retain the stent in a bronchial tube or tubule. A method of treatment of emphysema or other lung conditions or diseases in human or animal patients comprises placing an obturator in a bronchial tube or tubule of the patient so as to seal the tube or tubule against the passage of fluid past the obturator.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: March 20, 2012
    Assignee: Pulmonx Corporation
    Inventors: Sabaratnam Sabanathan, Thirumani Sabanathan, legal representative
  • Patent number: 8138147
    Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.
    Type: Grant
    Filed: January 6, 2009
    Date of Patent: March 20, 2012
    Assignee: Skinmedica, Inc.
    Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
  • Patent number: 8133471
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 13, 2012
    Assignee: New York University
    Inventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
  • Patent number: 8133497
    Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: March 13, 2012
    Assignee: The Foundry, LLC
    Inventors: Mark E. Deem, Hanson Gifford
  • Patent number: 8133737
    Abstract: The invention relates to a simple screening test for neoplasia, a precancerous condition, or cancer of the breast. A method is described whereby a breast cancer marker is detected in breast fluid. In a particular embodiment, the method involves treating samples of breast fluids with an aldehyde detecting reagent without any prewashing. The appearance in breast fluids of a marker that is detected by an aldehyde detecting reagent, such as a Schiff's reagent, correlates very well with the disease status of the breast cancer subjects from which the fluids were obtained. Screening test kits are also provided.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: March 13, 2012
    Assignee: Atossa Genetics, Inc.
    Inventors: Jiri Jan Krepinsky, Rudolf Furrer, Ka Sing Yeung
  • Patent number: 8132949
    Abstract: An illuminator film system may include one or more pre-cut sections of optical film applied to a waveguide to allow light to exit the waveguide through the film in a predetermined manner. The one or more pre-cut sections may be removed and reapplied during a procedure to redirect the light. A laminated illuminator film may be provided that uses a laminated optical film structure to direct light from a fiber optic input. Such a laminated illuminator film may be very low profile, low cost and easy to apply to a retractor for providing illumination during a surgical procedure.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: March 13, 2012
    Assignee: Invuity, Inc.
    Inventors: Alex Vayser, Kenneth B Trauner, Thomas L. Grey
  • Patent number: 8128968
    Abstract: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations and related conditions using such compositions.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: March 6, 2012
    Assignee: Tissuetech, Inc.
    Inventors: Ying-Ying Gao, Scheffer C. G. Tseng
  • Patent number: 8124749
    Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: February 28, 2012
    Assignee: Case Western Reserve University
    Inventors: Stephen M. Selkirk, Robert H. Miller
  • Patent number: 8122889
    Abstract: An oral device for improving airway patency comprises a tongue constraint and a negative pressure source. The tongue constraint engages the patient's tongue to maintain a clear region below the palate in an oral cavity. By applying a negative pressure in the clear region, an airway behind the soft palate or tongue of the patient can be maintained. The tongue constraint is usually connected to an anchor. The anchor may be held between the patient's teeth or may engage the inferior surface of the palate. Another oral device for improving airway patency comprises a lateral tongue structure and a negative pressure source.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: February 28, 2012
    Assignee: Apnicure, Inc.
    Inventors: Matthias Vaska, Jonathan Podmore, John Edwards Crowe, Sean Christopher Daniel
  • Patent number: D655642
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: March 13, 2012
    Inventor: Scott Francis Mogren